BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32768872)

  • 1. Fibrolamellar carcinoma: Challenging the challenge.
    Lamarca A; Frizziero M; Fulton A; McNamara MG; Filobbos R; Hubner RA; Wardell S; Valle JW
    Eur J Cancer; 2020 Sep; 137():144-147. PubMed ID: 32768872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
    Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
    Urabe T; Kaneko S; Matsushita E; Unoura M; Kobayashi K
    Oncology; 1998; 55(1):39-47. PubMed ID: 9428374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
    J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
    Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
    Yamashita T; Arai K; Sunagozaka H; Ueda T; Terashima T; Yamashita T; Mizukoshi E; Sakai A; Nakamoto Y; Honda M; Kaneko S
    Oncology; 2011; 81(5-6):281-90. PubMed ID: 22133996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Noda T; Nagano H; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Ohsuga K; Kim T; Tomoda K; Nakamura H; Monden M
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1221-5. PubMed ID: 16969014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrolamellar hepatocellular carcinoma in an infant and literature review.
    Cruz O; Laguna A; Vancells M; Krauel L; Medina M; Mora J
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):968-71. PubMed ID: 19131794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy.
    Fakih M
    Am J Ther; 2014; 21(6):e207-10. PubMed ID: 23676344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    Patt YZ; Hoque A; Roh M; Ellis L; Lozano R; Carrasco CH; Charnsangavej C; Cleary K
    Am J Clin Oncol; 1999 Apr; 22(2):209-13. PubMed ID: 10199464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Wu J; Huang WJ; Wang HY; Wang YF; Peng BG; Zhou Q
    Med Oncol; 2015 Mar; 32(3):65. PubMed ID: 25691293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
    Katsuramaki T; Furuhata T; Kimura Y; Yamaguchi K; Ohmura T; Hata F; Mukaiya M; Hirata K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1801-4. PubMed ID: 12402433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
    Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
    Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
    Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Marubashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Aozasa K; Monden M
    J Gastroenterol; 2004 Aug; 39(8):793-7. PubMed ID: 15338375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
    Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H; Kirikoshi H; Yoneda M; Higurashi T; Fujita K; Saito S; Inamori M; Takahashi H; Abe Y; Kubota K; Nakajima A
    Hepatogastroenterology; 2008; 55(86-87):1776-7. PubMed ID: 19102391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.